Sector Gamma AS Acquires 11,000 Shares of Humana Inc. $HUM

Key Points

• Sector Gamma AS significantly increased its ownership in Humana Inc. by 78.6% in the first quarter, culminating in a total of $6.62 million worth of stock holdings.
• Other institutional investors have also made substantial changes to their stakes, with Vanguard Group increasing its position by 8.9% and GAMMA Investing LLC showing a remarkable increase of 40,881.1%.
• Humana’s stock has received mixed ratings from analysts, with 18 analysts rating it as "Hold", while the average price target is set at $281.45.

Sector Gamma AS increased its position in shares of Humana Inc. (NYSE:HUM - Free Report) by 78.6% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 25,000 shares of the insurance provider's stock after purchasing an additional 11,000 shares during the quarter. Humana accounts for 2.1% of Sector Gamma AS's investment portfolio, making the stock its 20th biggest holding. Sector Gamma AS's holdings in Humana were worth $6,615,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in HUM. Vanguard Group Inc. increased its stake in Humana by 8.9% in the first quarter. Vanguard Group Inc. now owns 13,972,872 shares of the insurance provider's stock valued at $3,697,222,000 after purchasing an additional 1,143,662 shares during the last quarter. Pzena Investment Management LLC grew its position in Humana by 6.1% during the first quarter. Pzena Investment Management LLC now owns 3,828,923 shares of the insurance provider's stock valued at $1,013,133,000 after acquiring an additional 219,541 shares during the period. Davis Selected Advisers boosted its position in shares of Humana by 3.3% in the first quarter. Davis Selected Advisers now owns 2,331,343 shares of the insurance provider's stock worth $616,873,000 after buying an additional 74,434 shares during the period. T. Rowe Price Investment Management Inc. boosted its position in shares of Humana by 11.1% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,605,771 shares of the insurance provider's stock worth $407,401,000 after buying an additional 160,952 shares during the period. Finally, Northern Trust Corp boosted its position in shares of Humana by 14.5% in the fourth quarter. Northern Trust Corp now owns 1,216,195 shares of the insurance provider's stock worth $308,561,000 after buying an additional 153,739 shares during the period. 92.38% of the stock is owned by institutional investors and hedge funds.

Humana Stock Performance

Shares of NYSE:HUM traded down $2.2290 during midday trading on Wednesday, hitting $286.0210. The company's stock had a trading volume of 229,543 shares, compared to its average volume of 1,723,130. The stock has a market capitalization of $34.40 billion, a price-to-earnings ratio of 21.98, a PEG ratio of 1.69 and a beta of 0.44. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.95 and a current ratio of 1.95. Humana Inc. has a fifty-two week low of $206.87 and a fifty-two week high of $382.72. The stock's 50 day simple moving average is $244.92 and its 200 day simple moving average is $253.44.

Humana (NYSE:HUM - Get Free Report) last announced its quarterly earnings results on Wednesday, July 30th. The insurance provider reported $6.27 EPS for the quarter, missing analysts' consensus estimates of $6.32 by ($0.05). The business had revenue of $32.39 billion for the quarter, compared to the consensus estimate of $31.85 billion. Humana had a return on equity of 13.67% and a net margin of 1.28%.The firm's revenue for the quarter was up 9.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $6.96 EPS. Humana has set its FY 2025 guidance at 17.000- EPS. As a group, research analysts anticipate that Humana Inc. will post 16.47 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts recently commented on the company. Morgan Stanley cut their price target on Humana from $290.00 to $277.00 and set an "equal weight" rating on the stock in a research note on Thursday, July 31st. Raymond James Financial upgraded Humana from a "market perform" rating to an "outperform" rating and set a $315.00 price target on the stock in a research note on Thursday, May 1st. Bank of America cut their price target on Humana from $320.00 to $260.00 and set a "neutral" rating on the stock in a research note on Tuesday, June 17th. Cantor Fitzgerald reiterated a "neutral" rating and issued a $290.00 price target on shares of Humana in a research note on Thursday, May 1st. Finally, Piper Sandler cut their price objective on Humana from $288.00 to $272.00 and set a "neutral" rating on the stock in a research note on Thursday, July 31st. Seven analysts have rated the stock with a Buy rating and sixteen have given a Hold rating to the company. According to data from MarketBeat.com, Humana currently has a consensus rating of "Hold" and a consensus price target of $281.43.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.